Lexaria Bioscience Corp. (LEXX)
Automate Your Wheel Strategy on LEXX
With Tiblio's Option Bot, you can configure your own wheel strategy including LEXX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LEXX
- Rev/Share 0.0337
- Book/Share 0.2823
- PB 2.0434
- Debt/Equity 0.021
- CurrentRatio 3.9021
- ROIC -2.1576
- MktCap 11222365.0
- FreeCF/Share -0.5339
- PFCF -1.1488
- PE -0.996
- Debt/Assets 0.0173
- DivYield 0
- ROE -1.4935
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
5th study arm in 12-week Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee ("HREC") approval that was required before dosing can begin in the 5th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study") in Australia. This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms …
Read More
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Published: February 24, 2025 by: TheNewswire
Sentiment: Neutral
5 th study arm in 12-week Phase 1b Study receives lead clinical site approval Kelowna, British Columbia – February 24, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee (“HREC” ) approval that was required before dosing can begin in the 5 th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the “ Study ”) in Australia.
Read More
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Published: February 20, 2025 by: TheNewswire
Sentiment: Neutral
Pursuing the world's first-ever orally-dosed liraglutide Kelowna, British Columbia – February 20, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH™ enhancement technology.
Read More
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH™ enhancement technology. "Our ability to work with liraglutide, which went off-patent last year, is an opportunity that does not often present itself," said Rich Christopher, CEO of Lexaria.
Read More
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Published: February 11, 2025 by: TheNewswire
Sentiment: Neutral
Additions broaden DehydraTECH patent suite for Epilepsy Kelowna, British Columbia – TheNewswire - February 11, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH™ enhanced processing technology related to the treatment of epilepsy.
Read More
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
Additions broaden DehydraTECH patent suite for Epilepsy KELOWNA, BC / ACCESS Newswire / February 11, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH™ enhanced processing technology related to the treatment of epilepsy. "We are thrilled to have received broadened claims related to our proprietary DehydraTECH™ technology for the treatment of epilepsy," said Rich Christopher, CEO of Lexaria.
Read More
About Lexaria Bioscience Corp. (LEXX)
- IPO Date 2021-01-12
- Website https://www.lexariabioscience.com
- Industry Biotechnology
- CEO Richard C. Christopher
- Employees 7